Major histocompatibility complex (MHC) class II combined immunodeficiency (CID), also known as type II bare lymphocyte syndrome, is an autosomal recessive genetic disorder characterized by the complete lack of expression of MHC class II antigens. The defect results from a coordinated lack of transcription of all class II genes. Cell fusion studies using many patientand experimentally derived class II-negative cell lines have identified four distinct genetic complementation groups. In this report, we present genetic evidence that cell lines derived from two newly described MHC class II-deficient patients, KER and KEN, represent a fifth complementation group. In addition, the KER and KEN cell lines display a unique pattern of dyscoordinate regulation of their MHC class II genes, which is reflected in a new phenotype of in vivo promoter occupancy as revealed by in vivo genomic footprinting. These data point to a new defect that can result in the MHC class II-deficient phenotype.
M
HC class II antigens are highly polymorphic cell surface glycoproteins that are intimately involved in the generation of the immune response (1) . In the human, three isotypes (HLA-DR, -DQ, and -DP) of class II antigens are encoded by the HLA-D locus on chromosome 6. Each isotype consists of an 0~ and [3 chain, which together form a heterodimeric structure capable of binding exogenously derived peptides and presenting them to CD4 + Th cells (2) . The expression of class II molecules is limited to APC, such as B cells, macrophages, and dendritic cells, and to thymic epithelial cells, where expression is involved in the "education"of naive T cells before their exportation to the periphery (2, 3) . In addition to the constitutive and inducible expression on cells of the immune system, class II levels can also be induced on otherwise class II-negative cells by exposure to cytokines such as IFN-~ (2) .
The lack of expression of MHC class II molecules results in an immunodeficiency called MHC class II combined immunodeficiency (CID), 1 or the bare lymphocyte syndrome. The disease is characterized by the complete lack of 1Abbreviations used in this paper: B-LCL, B lymphoblastoid ceil line; CID, combined immunodeficiency; CIITA, class II tram-activator; P,.F-X, DNA-binding protein complex.
constitutive and inducible expression of class II antigens (4) . Patients with MHC class II CID demonstrate failure to thrive, subsequently develop overwhelming bacterial and viral infections, and usually die in childhood unless treated with bone marrow transplantation (4, 5) . The defect in gene expression is at the level of transcription and affects all class II genes coordinately (6) . Genetic studies of affected fanfilies have shown that the defect does not segregate with the MHC and suggest that the class I[ structural genes in such patients are intact (7) . The defect, rather, appears to be due to a malfunctioning trans-acting factor(s), as fusion of a class II-negative derivative of the Burkitt's lymphoma Raft to a class II-positive murine B lymphoma results in the restoration of expression of human class II antigens (8) . More extensive cell fusion studies, using a panel of CID patient EBV-transformed B lymphoblastoid cell lines (B-LCL), have identified four complementation groups, suggesting that four separate genetic lesions can give rise to the class IIdeficient phenotype (9) (10) (11) . In complementation groups I and IV, the lack of class II expression is thought to be due to a deficiency in a DNA-binding protein complex (R.F-X) that binds to the conserved X box in class II promoters (12, 13) . A cDNA for one member of the RF-X family, RF-X5, has recently been reported to restore class II expression in cell lines from complementation group IV (14) . The gene defective in complementation group II, termed class II tram-activator (CIITA), has recendy been isolated by expression cloning and has been shown to be sufficient to restore class II antigen expression in all cell lines from this complementation group (15) . The gene(s) defective in complementation group III remains to be identified.
Recently two new patients with MHC class II deficiency have been identified based on the lack of surface expression of class II antigens on their peripheral B cells and monocytes (16) . Unlike other class II CID patients, these histoidentical twin brothers have normal numbers of CD4 + cells and are able to mount both cellular and humoral immune responses, presumably because of extremely low levels of class II antigen expression in certain adherent mononuclear cells. Analysis of the transcription of class II genes in EBV-transformed B-LCL derived from these patients revealed a previously undescribed dyscoordinate pattern of expression: whereas levels of DRcx, DQot, and DPJ3 mRNA were approximately normal compared with controls, DRy, DQI3, and DP~ mRNA were completely absent (17) . Taken together, these results suggested that these patients represent a novel phenotype of MHC class II deficiency.
In this study, we have examined the expression of HLA-DR in transient heterokaryons formed by fusion between the patients' EBV-transformed B-LCL, KEN and KER, and cell lines from each of the four established complementation groups. Our data provide genetic evidence for a fifth complementation group of MHC class II deficiency characterized by a dyscoordinate expression of the class II genes. In addition, direct examination of the promoter regions of the class II genes in KEN and KER by in vivo genomic footprinting reveals that this dyscoordinate expression is associated with a new pattern of promoter occupancy different from those previously described for class II-negative cell lines.
Materials and Methods
Cell Lines. Experimentally derived class II-negative cell lines were maintained in RPMI 1640 medium supplemented with 10% FCS, 10 mM Hepes, 2 mM glutamine, 50 IxM 2-ME, penicillin (100 U/ml), and streptomycin (100 I~g/ml). 721.174 (18) is an EBV-transformed B-LCL that bears a homozygous deletion of the DR, DQ, and part of the DP region. RM3 (19) is a class II-negative derivative of the human Burkitt lymphoma Rail, whereas 6.1.6 (20) is derived from the class II-positive EBVtransformed B-LCL T5.1. All three cell lines are negative for DR, DQ, and DP expression.
The patient-derived EBV-transformed B-LCL KEN, KER, Nacera (21), BLS-1 (22) , TF (23) , and SJO (24) were maintained in RPMI 1640 medium supplemented with 20% FCS along with the additives listed above. EBV-transformed B-LCL derived from the mother and father of KER and KEN were grown in the same medium.
Cell Fusion. For the preparation of transient heterokaryons, 10 6 cells of each type were mixed in a 5-ml centrifuge tube and washed three times in serum-free medium. The cells were disaggregated by three passages through an 18-gauge needle and were washed once more in serum-free medium. Cell pellets were gently dispersed and warmed to 37~ Fusion was initiated by the dropwise addition of 0.1 ml PEG 1500 (50% wt/vol) (Boehringer-Mannheim Corp., Indianapolis, IN) over the course of 1 min. 5 ml of serum-flee medium was then added slowly over a 5-min period. Cells were rested at room temperature for 5 min, pelleted at 250 g for 3 rain, and plated in 5 ml of complete medium. After 48 h, the cells were analyzed for the expression of HLA-DR by incubation with FITC-conjugated anti-HLA-DR mAh L243 (Becton Dickinson & Co., San Jose, CA).
In Vivo Genomic Footprinting. Preparation of in vitro and in vivo methylated genomic DNA and piperidine treatment were as described (25) . Piperidine-treated genomic DNA (5 ~g) was used in ligation-mediated PCR as described (26) . Primers specific for the DR0t, DR{3, and the DQ{3 promoter coding strands have been described (25, 27) .
RNA Analysis. Total cellular RNA was extracted as described (28) . 20/*g of RNA was electrophoresed on 1.2% agarose gels, blotted to GeneScreen (DuPont-NEN, Boston, MA), and hybridized with radioactive probes generated by random-hexamer labeling.
Results
Complementation Analysis. To determine if the MHC class II-deficient cell lines KER and KEN belong to any of the four previously defined CID complementation groups, transient heterokaryons were prepared and analyzed 48 h after fusion for expression of HLA-DR antigens. Cells from both KEN and KER were fused to the following EBVtransformed B-LCL representing all four known CID complementation groups: Nacera and BLS-1 (group 1), RM3 (group II), 6.1.6 (group III), and TF (group-IV). tn addition, 721.174, an experimentally derived EBV-transformed B-LCL that lacks the class II structural genes, was used as a further control. Each fusion experiment also included fusions between pairs of cells from groups I, II, III, and IV.
Results of multiple fusion experiments are summarized in Table 1 . Fusion of KEN to KER yielded no class II-positive heterokaryons, whereas fusion of either cell hne to 721.174 caused reexpression of HLA-DR. These results suggest that both the transcribed (DRot, DQot, and DPJ3) and the nontranscribed (DR{3, DQJ3, and DPet) class II structural genes in KER and KEN are functionally intact and that the nontranscribed genes can be expressed in the presence of the appropriate trans-acdng factor. Fusion of KEN or KER to cell lines from groups I, II, and IV invariably gave rise to heterokaryons that showed expression of HLA-DR and thus clearly demonstrate that both KER and KEN do not belong to any of these complementation groups. Although the only cell line in group III, 6.1.6, has a small percentage of class II-positive revertants, repeated fusions, scored bhndly, indicated that both KER and KEN can complement 6.1.6 and thus do not belong to complementation group III. Fig. 1 shows the results from representative fusion experiments between KER and 721.174, Nacera (group I), RM3 (group II), and TF (group IV). Based on this analysis, KER and KEN clearly define a new corn- , we examined the promoters o f three class II genes in these cells by in vivo genomic footprinting. In both K E R and KEN, the DRot gene is transcribed at normal levels, and indeed, the DRc~ promoter is occupied in both.
The pattern of protection of the X1, X2, Y, and the DRcxspecific octamer elements was identical to that seen in a class II-positive EBV-transformed B-LCL derived from the mother o f the patients (Fig. 2, /eft) . In contrast, the promoter o f the nontranscribed DR[3 gene is not protected in either K E R or K E N (Fig. 2, right) . Footprint analysis o f the DQ[3 promoter, which is nontranscribed in K E R and KEN, also revealed the bare phenotype (data not shown). These in vivo genomic footprinting studies suggest that in group V CID, those class II genes that are actively transcribed (DRop, DQot, and DP[3) have occupied promoters, whereas those genes that are not transcribed (DR[3, DQ[3, and DPo 0 have bare promoters. Thus, in addition to defin- 
Discussion
The immunological profile and the unique pattern of expression of class II m R N A in the class II-deficient patients KER. and K E N suggested that they represent a new phenotype of M H C class II CID. Previously identified class II-negative cell lines, both patient derived and experimentally generated, have been placed into four complementation groups by somatic cell fusion analysis, implying that at least four separate genetic lesions can lead to the class I Inegative phenotype. W e extended that type of genetic analysis to K E R and K E N and showed that they define a new CID complementation group and presumably represent a mutation in another gene critical for class II antigen expression. KER. and K E N also exhibit a mixed pattern of in vivo M H C class II promoter occupancy that correlates completely with the transcriptional status o f the various class II genes: those genes that are transcribed (Dkc~, DQot, and DP[3) have an occupied promoter, whereas those genes that are transcriptionally silent (DR[3, DQ[3, and DPcx) have bare promoters. This dyscoordinate regulation between the ix and [3 chains of a given HLA isotype is the hallmark of complementaion group V.
There are numerous examples of cell lines, both normal and malignant, that show a dissociation of expression among the three class II isotypes. A derivative of the Burkitt's lymphoma Jijoye, clone 13, for example, expresses D Q but not D R and DP (33) . In human dermal fibroblasts, treatment with IFN-~/ induces detectable D R and DP but not D Q (34) . Malignant B cells have been described that fail to express one or more specific class II isotypes (35, 36) . These studies, taken together, suggest that certain class II genes may be regulated differentially at the transcriptional level. None of these examples, however, reflect the pattern of dyscoordinate regulation seen in K E R and KEN: the transcription of a given M A chain but not the [3 chain (or vice versa) for a specific H L A -D isotype.
Analysis of cell lines from the four previously described CID complementation groups by in vivo genomic footprinting has suggested two different mechanisms for the lack o f transcription o f class II genes (25, 27) . The bare promoter phenotype points to a defect in promoter accessibility since factors recognizing some or all o f the promoter elements conserved among class II genes can be detected in vitro. The occupied promoter phenotype suggests a defect in an activation domain of either a promoter-binding protein or a protein that interacts with promoter-binding factors. Indeed, CIITA, the gene defective in complementation group II, does not itself bind D N A but appears to function as a coactivator (15) . In cells of the B lineage, where the expression o f M H C class II antigens is developmentally regulated, the occupied promoter phenotype correlates with transcriptionally active class II genes, as in mature B cells, whereas the bare promoter phenotype is observed in pre-B cells and in plasma cells, where the class II genes are transcriptionally silent (37) . These results imply that promoter accessibility is a primary determinant of class II expression and that such accessibility may be developmentally regulated.
The dyscoordinate regulation of the class II genes as well as the mixed pattern of promoter occupancy observed in K E N and K E R suggest that the defect in complementation group V may have unmasked a previously unrecognized level of regulation of the M H C class II genes. O f the many factors known to bind to the highly conserved W, X1, X2, and Y elements c o m m o n to all class II promoters, not alI factors bind with equal affinity to all promoters. One o f these factors, RFX, shows a distinct hierarchy o f binding to the ix chain promoters: a high affinity for DRix, a reduced affinity for DPcx, and a very low affinity for DQix. existent (38, 39) . Another factor that binds to the X box motif, X2BP, shows a completely different pattern of promoter-binding affinities with DP[3 >DRcx >DRI3, whereas no binding is seen to DQot, DQJ3, or DPtx (40) . Finally, hXBP1 binds only to the X2 boxes of the DR[3 and DP [3 promoters (41) . These studies suggest that the combination of factors necessary to achieve coordinate regulation of the six class II ot and MA chain genes may in fact differ from gene to gene. Thus, it is possible that the dyscoordinate regulation of the class II genes in complementation group V might be due to a mutational inactivation of a promoter-binding factor required for the expression of DRJ3, DQJ3, and DPe~, but not for DRot, DQet, and DP[3. None of the factors described to date, however, fit this particular pattern of binding affinities.
Another explanation for the pattern of class II gene expression in group V is suggested by the striking fact that all of the transcriptionally active class II genes in KEN and KER share the same transcriptional orientation within the MHC class II locus. Conversely, those genes that are transcriptionally silent share the opposite transcriptional orientation. Thus, DRa, DQot, and DPI3 are transcribed from right to left, whereas DR[3, DQ[3, DPo~ are all transcribed from left to right, as diagrammed in Fig. 4 . In addition to the defect in the transcription of certain class II genes, KER and KEN also fail to express DMA and DMB, genes whose promoters are quite homologous to the those of the class II structural genes and are thought to share a common regulatory mechanism (29, 30, 42) . The orientation of these two nontranscribed genes within the HLA-D region of the MHC is the same as those class II genes not expressed in KER and KEN; that is, they are transcribed from left to right. It seems unlikely that the lack of transcription of DR[3, DQ[3, DPc~, DMA, and DMB could result from individual mutations in the promoters of these genes. Rather, this global lack of transcription is more reminiscent of the effects of a locus control region, albeit one that exerts its effects directionally on class II-like promoters. To our knowledge, no example of such a unidirectional locus control region has been reported.
The defect in group V CID, in addition to its effects on isotype-specific dysregulation, may also play a role in cell type--specific expression of the class II genes. Although, there is no class II protein detectable on the surface of either primary or EBV-transformed B-LCL from KER and KEN, the fact that they have normal levels of CD4 + cells suggests that these patients must express class II antigens in the thymus (43) . Furthermore, since both patients are able to mount specific antibody responses, some class II must be expressed in the periphery (16) . Indeed, we have suggested that there may be HLA-DR present on certain adherent monocyte populations at levels too low to be detected by flow cytometry based on the finding of apparently intact intracellular DRot and DR[3 in these cells (17) . This would suggest that the regulation of the class II genes in B cells, thymic epithelial cells, and macrophages may differ. Further, such cell type-specific transcriptional differences might also be attributable to the effects of the gene defective in group V CID. Identification of the gene(s) responsible for the dyscoordinate regulation and the differences in tissue-specific expression of the MHC class II genes in group V CID may provide insight into the aberrant expression of class II antigens in certain autoimmune diseases. The ability to manipulate the immune system by regulating patterns of expression of class II in an isotype-and cell type--specific manner suggests more gently tuned immunomodulatory treatment options than those currendy available.
